1Singh, S (2007) From exotic spice to modern drug? Cell 130, 765–768.
3Jain, V, Prasad, V, Pal, R, et al. (2007) Standardization and stability studies of neuroprotective lipid soluble fraction obtained from Curcuma longa. J Pharm Biomed Anal 44, 1079–1086.
4Prakash, P, Misra, A, Surin, WR, et al. (2011) Anti-platelet effects of curcuma oil in experimental models of myocardial ischemia–reperfusion and thrombosis. Thromb Res 127, 111–118.
5Prakash, P, Khanna, V, Singh, V, et al. (2011) Atorvastatin protects against ischemia-reperfusion injury in fructose-induced insulin resistant rats. Cardiovasc Drugs Ther 25, 285–297.
6Dohare, P, Garg, P, Sharma, U, et al. (2008) Neuroprotective efficacy and therapeutic window of curcuma oil: in rat embolic stroke model. BMC Complement Altern Med 8, 55.
7Dohare, P, Varma, S & Ray, M (2008) Curcuma oil modulates the nitric oxide system response to cerebral ischemia/reperfusion injury. Nitric Oxide 19, 1–11.
8Rathore, P, Dohare, P, Varma, S, et al. (2008) Curcuma oil: reduces early accumulation of oxidative product and is anti-apoptogenic in transient focal ischemia in rat brain. Neurochem Res 33, 1672–1682.
9Jayaprakasha, GK, Jena, BS, Negi, PS, et al. (2002) Evaluation of antioxidant activities and antimutagenicity of turmeric oil: a byproduct from curcumin production. Z Naturforsch C 57, 828–835.
10Sandur, SK, Pandey, MK, Sung, B, et al. (2007) Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis 28, 1765–1773.
11Lee, Y (2009) Activation of apoptotic protein in U937 cells by a component of turmeric oil. BMB Rep 42, 96–100.
12Liju, VB, Jeena, K & Kuttan, R (2011) An evaluation of antioxidant, anti-inflammatory, and antinociceptive activities of essential oil from Curcuma longa L. Indian J Pharmacol 43, 526–531.
13Li, AC & Glass, CK (2004) PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res 45, 2161–2173.
14Valasek, MA, Clarke, SL & Repa, JJ (2007) Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse. J Lipid Res 48, 2725–2735.
15Rakhshandehroo, M, Knoch, B, Muller, M, et al. (2010) Peroxisome proliferator-activated receptor alpha target genes. PPAR Res 2010, , article ID 612089.
16Briand, F, Treguier, M, Andre, A, et al. (2010) Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model. J Lipid Res 51, 763–770.
17Singh, V, Tiwari, RL, Dikshit, M, et al. (2009) Models to study atherosclerosis: a mechanistic insight. Curr Vasc Pharmacol 7, 75–109.
18Zhang, Z, Wang, H, Jiao, R, et al. (2009) Choosing hamsters but not rats as a model for studying plasma cholesterol-lowering activity of functional foods. Mol Nutr Food Res 53, 921–930.
19Singh, V, Jain, M, Prakash, P, et al. (2011) A time course study on prothrombotic parameters and their modulation by anti-platelet drugs in hyperlipidemic hamsters. J Physiol Biochem 67, 205–216.
20Jain, M, Barthwal, MK, Haq, W, et al. (2012) Synthesis and pharmacological evaluation of novel arginine analogs as potential inhibitors of acetylcholine-induced relaxation in rat thoracic aortic rings. Chem Biol Drug Des 79, 459–469.
21Khanna, V, Jain, M, Barthwal, MK, et al. (2011) Vasomodulatory effect of novel peroxovanadate compounds on rat aorta: role of rho kinase and nitric oxide/cGMP pathway. Pharmacol Res 64, 274–282.
22Hara, A & Radin, NS (1978) Lipid extraction of tissues with a low-toxicity solvent. Anal Biochem 90, 420–426.
23Poirier, J, Cockell, KA, Scoggan, KA, et al. (2012) High-dose supplemental selenite to male Syrian hamsters fed hypercholesterolaemic diets alters Ldlr, Abcg8 and Npc1l1 mRNA expression and lowers plasma cholesterol concentrations. Br J Nutr 108, 257–266.
24Tiwari, RL, Singh, V, Singh, A, et al. (2011) IL-1R-associated kinase-1 mediates protein kinase Cdelta-induced IL-1beta production in monocytes. J Immunol 187, 2632–2645.
25Lee, HS (2006) Antiplatelet property of Curcuma longa L. rhizome-derived ar-turmerone. Bioresour Technol 97, 1372–1376.
26Reagan-Shaw, S, Nihal, M & Ahmad, N (2008) Dose translation from animal to human studies revisited. FASEB J 22, 659–661.
27Hastak, K, Lubri, N, Jakhi, SD, et al. (1997) Effect of turmeric oil and turmeric oleoresin on cytogenetic damage in patients suffering from oral submucous fibrosis. Cancer Lett 116, 265–269.
28Joshi, J, Ghaisas, S, Vaidya, A, et al. (2003) Early human safety study of turmeric oil (Curcuma longa oil) administered orally in healthy volunteers. J Assoc Physicians India 51, 1055–1060.
29Ng, TP, Chiam, PC, Lee, T, et al. (2006) Curry consumption and cognitive function in the elderly. Am J Epidemiol 164, 898–906.
30Hutchins-Wolfbrandt, A & Mistry, AM (2011) Dietary turmeric potentially reduces the risk of cancer. Asian Pac J Cancer Prev 12, 3169–3173.
31Guo, Q, Wang, PR, Milot, DP, et al. (2001) Regulation of lipid metabolism and gene expression by fenofibrate in hamsters. Biochim Biophys Acta 1533, 220–232.
32Mukherjee, R, Locke, KT, Miao, B, et al. (2008) Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist. J Pharmacol Exp Ther 327, 716–726.
33Srivastava, RA (2011) Evaluation of anti-atherosclerotic activities of PPAR-alpha, PPAR-gamma, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters. Atherosclerosis 214, 86–93.
34Davis, HR Jr, Compton, DS, Hoos, L, et al. (2001) Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol 21, 2032–2038.
35Valasek, MA, Repa, JJ, Quan, G, et al. (2008) Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters. Am J Physiol Gastrointest Liver Physiol 295, G813–G822.
36Goya, K, Sumitani, S, Xu, X, et al. (2004) Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 24, 658–663.
37Lecker, JL, Matthan, NR, Billheimer, JT, et al. (2010) Impact of dietary fat type within the context of altered cholesterol homeostasis on cholesterol and lipoprotein metabolism in the F1B hamster. Metabolism 59, 1491–1501.
38Kalaany, NY & Mangelsdorf, DJ (2006) LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 68, 159–191.
39Davis, HR Jr, Basso, F, Hoos, LM, et al. (2008) Cholesterol homeostasis by the intestine: lessons from Niemann–Pick C1 Like 1 [NPC1L1). Atheroscler Suppl 9, 77–81.
40Staels, B, Dallongeville, J, Auwerx, J, et al. (1998) Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98, 2088–2093.
41Konig, B, Koch, A, Spielmann, J, et al. (2007) Activation of PPARalpha lowers synthesis and concentration of cholesterol by reduction of nuclear SREBP-2. Biochem Pharmacol 73, 574–585.
42Van Rooyen, DM & Farrell, GC (2011) SREBP-2: a link between insulin resistance, hepatic cholesterol, and inflammation in NASH. J Gastroenterol Hepatol 26, 789–792.
43Yu, L, Li-Hawkins, J, Hammer, RE, et al. (2002) Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest 110, 671–680.
44Hossain, MA, Tsujita, M, Gonzalez, FJ, et al. (2008) Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes. J Cardiovasc Pharmacol 51, 258–266.
45Duval, C, Touche, V, Tailleux, A, et al. (2006) Niemann–Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. Biochem Biophys Res Commun 340, 1259–1263.
46Forcheron, F, Cachefo, A, Thevenon, S, et al. (2002) Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes 51, 3486–3491.
47Beaven, SW & Tontonoz, P (2006) Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu Rev Med 57, 313–329.
48Srivastava, RA & He, S (2010) Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster. Mol Cell Biochem 345, 197–206.
49Saurav, A, Kaushik, M & Mohiuddin, SM (2012) Fenofibric acid for hyperlipidemia. Expert Opin Pharmacother 13, 717–722.
50Li, G, Liu, X, Zhu, H, et al. (2009) Insulin resistance in insulin-resistant and diabetic hamsters (Mesocricetus auratus) is associated with abnormal hepatic expression of genes involved in lipid and glucose metabolism. Comp Med 59, 449–458.
51Marinho, M, Oliveira-Junior, IS, Monteiro, CM, et al. (2009) Pulmonary disease in hamsters infected with Leptospira interrogans: histopathologic findings and cytokine mRNA expressions. Am J Trop Med Hyg 80, 832–836.
52Kim, H, Bartley, GE, Rimando, AM, et al. (2010) Hepatic gene expression related to lower plasma cholesterol in hamsters fed high-fat diets supplemented with blueberry peels and peel extract. J Agric Food Chem 58, 3984–3991.